A case of Guillain-Barre syndrome after the second dose of AstraZeneca COVID-19 vaccination

Coronavirus disease 2019 (COVID-19) is a novel virus that primarily involves the respiratory system. Due to the COVID-19 pandemic, an extensive vaccination program is underway worldwide. Herein, we present a 68-year-old woman with paresthesia of both hands associated with gait instability, which sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Bazrafshan, Hanieh, Mohamadi Jahromi, Leila Sadat, Parvin, Reyhaneh, Ashraf, Alireza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bayçınar Medical Publishing 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366477/
https://www.ncbi.nlm.nih.gov/pubmed/35989967
http://dx.doi.org/10.5606/tftrd.2022.9984
Descripción
Sumario:Coronavirus disease 2019 (COVID-19) is a novel virus that primarily involves the respiratory system. Due to the COVID-19 pandemic, an extensive vaccination program is underway worldwide. Herein, we present a 68-year-old woman with paresthesia of both hands associated with gait instability, which started three to four days after receiving the second dose of Oxford/AstraZeneca vaccine against the COVID-19 infection. The acute inflammatory demyelinating polyradiculoneuropathy subtype of the Guillain-Barre syndrome, which is the most common subtype, was diagnosed. Regardless of the beneficial effects of the vaccines, this case report aimed to evaluate their severe complications, such as Guillain-Barre syndrome, to reduce their occurrence in the future.

Ejemplares similares